Actinium Pharmaceuticals, Inc. 8-K

What Happened Actinium Pharmaceuticals, Inc. (ATNM) filed a Form 8‑K on May 29, 2026 disclosing that on May 27, 2026 it received a notice from NYSE American that it does not meet the exchange’s continued listing standards under Section 1003(a)(ii)/(iii). The filing states the company reported stockholders’ equity of approximately $2.3 million as of March 31, 2026 (below the $4.0 million threshold) and has recorded net losses in each of the last five fiscal years ended December 31, 2025. The company must submit a plan to regain compliance by June 26, 2026 and, if accepted, must return to compliance by November 27, 2027. The notice does not immediately affect trading; ATNM will continue trading on NYSE American with a “.BC” indicator. The company also issued a May 29, 2026 press release that included the notice and an update on its ATNM‑400 development program.

Key Details

• Stockholders’ equity: ~ $2.3 million as of March 31, 2026 (NYSE requirement: $4.0 million).
• Loss history: Net losses in each of the last five fiscal years ended December 31, 2025.
• Deadlines: Plan due to NYSE American by June 26, 2026; compliance required by November 27, 2027 if plan accepted.
• Trading status: Common stock continues to trade on NYSE American under symbol “ATNM” with a “.BC” indicator; delisting proceedings would follow if no acceptable plan or insufficient progress.

Why It Matters This notice signals a regulatory risk that could lead to delisting if Actinium cannot restore the required equity or otherwise satisfy NYSE American’s standards. Delisting (or even the threat of it) can reduce liquidity, limit investor access to the stock, and increase downward pressure on the share price. The company has the right to submit a compliance plan and to appeal any delisting determination, but the filing expressly warns there is no assurance it will regain compliance. Investors should monitor the company’s June 26, 2026 plan submission, any NYSE response, and further updates on the ATNM‑400 program provided in the company’s press releases.